Familial Hyperlipidemia Caused by Apolipoprotein B Mutation in the Pediatric Amish Population: A Mini Review

Area of Science:

• Genetics
• Cardiovascular Medicine
• Biochemistry

Background:

• Familial Hypercholesterolemia (FH) is an autosomal dominant genetic disorder.
• It leads to elevated low-density lipoprotein cholesterol (LDL-C) and premature cardiovascular disease (CVD).
• Mutations in LDLR, APOB, and PCSK9 genes are primary causes of FH.

Purpose of the Study:

• To provide an overview of Apolipoprotein B (ApoB) metabolism and clinical manifestations of APOB mutations.
• To highlight the significance of the APOB p.R3527Q founder variant in the Pennsylvania Amish population for FH diagnosis and treatment.
• To discuss the impact of APOB mutations on lipid profiles and cardiovascular risk.

Main Methods:

• Review of existing literature on FH, APOB metabolism, and genetic variants.
• Analysis of clinical manifestations associated with APOB mutations, particularly APOB p.R3527Q.
• Discussion of lipid profile changes (LDL-C, LDL-P, ApoB) and their clinical implications.

Main Results:

• APOB mutations account for 5% of FH cases, with the p.R3527Q variant prevalent in the Amish population (12%).
• APOB is a critical atherogenic lipoprotein and determinant of hypercholesterolemia.
• Patients with APOB mutations exhibit altered LDL cholesterol, LDL particles, and ApoB levels, increasing atherosclerosis risk.

Conclusions:

• Understanding APOB p.R3527Q is crucial for diagnosing and treating FH in the Amish community.
• APOB mutations contribute significantly to FH and cardiovascular risk, especially in specific populations.
• Elevated ApoB levels and altered LDL particle characteristics are key indicators of increased atherosclerotic risk in FH patients.